Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.
Elefanti L, Sacco G, Stagni C, Rastrell M, Menin C, Russo I, Alaibac M
Oncol Lett. 2016 Jul;12(1):275-280.
PMID: 27347137 [PubMed]

Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data.
Chen J, Xu Y, Zhou Y, Wang Y, Zhu H, Shi Y
Oncotarget. 2016 Jun 17;():.
PMID: 27344178 [PubMed - as supplied by publisher]

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Rajkumar S, Watson IR
Br J Cancer. 2016 Jun 23;():.
PMID: 27336610 [PubMed - as supplied by publisher]

Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients.
Tas F, Bilgin E, Karabulut S, Duranyildiz D
Mol Clin Oncol. 2016 Jul;5(1):195-200.
PMID: 27330797 [PubMed]

The effect of time to sentinel lymph node biopsy on cutaneous melanoma survival.
Fortes C, Mastroeni S, Caggiati A, Passarelli F, Zappalà A, Capuano M, Bono R, Nudo M, Marino C, Michelozzi P
Am J Surg. 2016 May 12;():.
PMID: 27266393 [PubMed - as supplied by publisher]


NCBI's Disclaimer and Copyright notice